Hiraoka et al. concluded by suggesting that continuous STAT3 activation promoted adenomyosis development and that STAT3 inhibition could be a promising treatment strategy in patients suffering from adenomyosis [12]. The gene discussed is STAT3; the disease is adenomyosis.